Assessing the synergy between cholinomimetics and memantine as augmentation therapy in cognitive impairment in schizophrenia. A virtual human patient trial using quantitative systems pharmacology

Frontiers in Pharmacology

Volumn 6, Issue SEP, 2015, Pages

  Geerts, Hugo ^a,b   Roberts, Patrick ^c   Spiros, Athan ^a  

^a In Silico Biosciences   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c WASHINGTON STATE UNIVERSITY   (United States)

Author keywords

Antipsychotics; Cholinomimetic; Cognition; Polypharmacy; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DONEPEZIL; GALANTAMINE; HALOPERIDOL; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ARTICLE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPUTER MODEL; COMPUTER SIMULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; MENTAL PERFORMANCE; OUTCOME ASSESSMENT; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; SMOKING;

EID: 84944722177     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2015.00198     Document Type: Article

References (65)

1. Akhondzadeh, S., Gerami, M., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Abbasi, S. H., et al. (2008). A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 1810-1815. doi: 10.1016/j.pnpbp.2008.08.001
2. Beckmann, H., and Laux, G. (1990). Guidelines for the dosage of antipsychotic drugs. Acta Psychiatr. Scand. 358, 63-66. doi: 10.1111/j.1600-0447.1990.tb05291.x
3. Besnard, J., Ruda, G. F., Setola, V., Abecassis, K., Rodriguiz, R. M., Huang, X. P., et al. (2012). Automated design of ligands to polypharmacological profiles. Nature 492, 215-220. doi: 10.1038/nature11691
4. Beudel, M., Little, S., Pogosyan, A., Ashkan, K., Foltynie, T., Limousin, P., et al. (2015). Tremor reduction by deep brain stimulation is associated with gamma power suppression in Parkinson's disease. Neuromodulation 18, 349-354. doi: 10.1111/ner.12297
5. Brody, A. L., Mandelkern, M. A., London, E. D., Olmstead, R. E., Farahi, J., Scheibal, D., et al. (2006). Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch. Gen. Psychiatry 63, 907-915. doi: 10.1001/archpsyc.63.8.907
6. Buchanan, R. W., Conley, R. R., Dickinson, D., Ball, M. P., Feldman, S., Gold, J. M., et al. (2008). Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am. J. Psychiatry 165, 82-89. doi: 10.1176/appi.ajp.2007.07050724
7. Buisson, B., Gopalakrishnan, M., Arneric, S. P., Sullivan, J. P., and Bertrand, D. (1996). Human alpha4beta2 neuronal nicotinic acetylcholine receptor in HEK 293 cells: a patch-clamp study. J. Neurosci. 16, 7880-7891.
8. Bymaster, F. P., Calligaro, D. O., Falcone, J. F., Marsh, R. D., Moore, N. A., Tye, N. C., et al. (1996). Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14, 87-96. doi: 10.1016/0893-133X(94)00129-N
9. Choi, K. H., Wykes, T., and Kurtz, M. M. (2013). Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy. Br. J. Psychiatry 203, 172-178. doi: 10.1192/bjp.bp.111.107359
10. Coyle, J. T. (2006). Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell. Mol. Neurobiol. 26, 365-384. doi: 10.1007/s10571-006-9062-8
11. Dalack, G. W., Healy, D. J., and Meador-Woodruff, J. H. (1998). Nicotine dependence in schizophrenia: clinical phenomena and laboratory findings. Am. J. Psychiatry 155, 1490-1501. doi: 10.1176/ajp.155.11.1490
12. Darreh-Shori, T., Kadir, A., Almkvist, O., Grut, M., Wall, A., Blomquist, G., et al. (2008). Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine. Neurobiol. Aging 29, 168-184. doi: 10.1016/j.neurobiolaging.2006.09.020
13. Désaméricq, G., Schurhoff, F., Meary, A., Szöke, A., Macquin-Mavier, I., Bachoud-Lévi, A. C., et al. (2014). Long-term neurocognitive effects of antipsychotics in schizophrenia: a network meta-analysis. Eur. J. Clin. Pharmacol. 70, 127-134. doi: 10.1007/s00228-013-1600-y
14. Deutsch, S. I., Schwartz, B. L., Schooler, N. R., Rosse, R. B., Mastropaolo, J., and Gaskins, B. (2008). First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy. Clin. Neuropharmacol. 31, 34-39. doi: 10.1097/wnf.0b013e31806462ba
15. Dunlop, J., and Brandon, N. J. (2015). Schizophrenia drug discovery and development in an evolving era: are new drug targets fulfilling expectations? J. Psychopharmacol. 29, 230-238. doi: 10.1177/0269881114565806
16. Durstewitz, D., and Seamans, J. K. (2008). The dual-state theory of prefrontal cortex dopamine function with relevance to catechol-o-methyltransferase genotypes and schizophrenia. Biol. Psychiatry 64, 739-749. doi: 10.1016/j.biopsych.2008.05.015
17. Dyer, M. A., Freudenreich, O., Culhane, M. A., Pachas, G. N., Deckersbach, T., Murphy, E., et al. (2008). High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia. Schizophr. Res. 102, 88-95. doi: 10.1016/j.schres.2007.12.491
18. Gauthier, S., and Molinuevo, J. L. (2013). Benefits of combined cholinesterase inhibitor and memantine treatment in moderate-severe Alzheimer's disease. Alzheimers Dement. 9, 326-331. doi: 10.1016/j.jalz.2011.11.005
19. Geerts, H. (2009). Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 23, 915-926. doi: 10.2165/11310890-000000000-00000
20. Geerts, H., Roberts, P., and Spiros, A. (2013). A quantitative system pharmacology computer model for cognitive deficits in schizophrenia. CPT Pharmacometrics Syst. Pharmacol. 2, e36. doi: 10.1038/psp.2013.12
21. Geerts, H., Spiros, A., Roberts, P., Twyman, R., Alphs, L., and Grace, A. A. (2012). Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS ONE 7:e49732. doi: 10.1371/journal.pone.0049732
22. Grady, S. R., Wageman, C. R., Patzlaff, N. E., and Marks, M. J. (2012). Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include alpha5 or alpha6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology 62, 1935-1943. doi: 10.1016/j.neuropharm.2011.12.026
23. Green, M. F., and Nuechterlein, K. H. (2004). The MATRICS initiative: developing a consensus cognitive battery for clinical trials. Schizophr. Res. 72, 1-3. doi: 10.1016/j.schres.2004.09.006
24. Iwanaga, Y., Kimura, T., Miyashita, N., Morikawa, K., Nagata, O., Itoh, Z., et al. (1994). Characterization of acetylcholinesterase-inhibition by itopride. Jpn. J. Pharmacol. 66, 317-322. doi: 10.1254/jjp.66.317
25. Kadra, G., Stewart, R., Shetty, H., Jackson, R. G., Greenwood, M. A., Roberts, A., et al. (2015). Extracting antipsychotic polypharmacy data from electronic health records: developing and evaluating a novel process. BMC Psychiatry 15:166. doi: 10.1186/s12888-015-0557-z
26. Keefe, R. S., Malhotra, A. K., Meltzer, H. Y., Kane, J. M., Buchanan, R. W., Murthy, A., et al. (2008). Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. Neuropsychopharmacology 33, 1217-1228. doi: 10.1038/sj.npp.1301499
27. Kishi, T., and Iwata, N. (2013). NMDA receptor antagonists interventions in schizophrenia: meta-analysis of randomized, placebo-controlled trials. J. Psychiatr. Res. 47, 1143-1149. doi: 10.1016/j.jpsychires.2013.04.013
28. Kitchen, H., Rofail, D., Heron, L., and Sacco, P. (2012). Cognitive impairment associated with schizophrenia: a review of the humanistic burden. Adv. Ther. 29, 148-162. doi: 10.1007/s12325-012-0001-4
29. Kohler, C. G., Martin, E. A., Kujawski, E., Bilker, W., Gur, R. E., and Gur, R. C. (2007). No effect of donepezil on neurocognition and social cognition in young persons with stable schizophrenia. Cogn. Neuropsychiatry 12, 412-421. doi: 10.1080/13546800701307263
30. Koola, M. M., Buchanan, R. W., Pillai, A., Aitchison, K. J., Weinberger, D. R., Aaronson, S. T., et al. (2014). Potential role of the combination of galantamine and memantine to improve cognition in schizophrenia. Schizophr. Res. 157, 84-89. doi: 10.1016/j.schres.2014.04.037
31. Kotermanski, S. E., and Johnson, J. W. (2009). Mg2+ imparts NMDA receptor subtype selectivity to the Alzheimer's drug memantine. J. Neurosci. 29, 2774-2779. doi: 10.1523/jneurosci.3703-08.2009
32. Kotermanski, S. E., Wood, J. T., and Johnson, J. W. (2009). Memantine binding to a superficial site on NMDA receptors contributes to partial trapping. J. Physiol. 587, 4589-4604. doi: 10.1113/jphysiol.2009.176297
33. Lee, S. W., Lee, J. G., Lee, B. J., and Kim, Y. H. (2007). A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia. Int. Clin. Psychopharmacol. 22, 63-68. doi: 10.1097/YIC.0b013e3280117feb
34. Lindenmayer, J. P., and Khan, A. (2011). Galantamine augmentation of long-acting injectable risperidone for cognitive impairments in chronic schizophrenia. Schizophr. Res. 125, 267-277. doi: 10.1016/j.schres.2010.08.021
35. Little, S., Pogosyan, A., Neal, S., Zavala, B., Zrinzo, L., Hariz, M., et al. (2013). Adaptive deep brain stimulation in advanced Parkinson disease. Ann. Neurol. 74, 449-457. doi: 10.1002/ana.23951
36. Liu, J., Ogden, A., Comery, T. A., Spiros, A., Roberts, P., and Geerts, H. (2014). Prediction of efficacy of vabicaserin, a 5-HT2C agonist, for the treatment of schizophrenia using a quantitative systems pharmacology model. CPT Pharmacometrics Syst. Pharmacol. 3, e111. doi: 10.1038/psp.2014.7
37. McClure-Begley, T. D., King, N. M., Collins, A. C., Stitzel, J. A., Wehner, J. M., and Butt, C. M. (2009). Acetylcholine-stimulated [3H]GABA release from mouse brain synaptosomes is modulated by alpha4beta2 and alpha4alpha5beta2 nicotinic receptor subtypes. Mol. Pharmacol. 75, 918-926. doi: 10.1124/mol.108.052274
38. Meyer-Lindenberg, A., Miletich, R. S., Kohn, P. D., Esposito, G., Carson, R. E., Quarantelli, M., et al. (2002). Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia. Nat. Neurosci. 5, 267-271. doi: 10.1038/nn804
39. Monyer, H., Burnashev, N., Laurie, D. J., Sakmann, B., and Seeburg, P. H. (1994). Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron 12, 529-540. doi: 10.1016/0896-6273(94)90210-0
40. Nicholas, T., Duvvuri, S., Leurent, C., Raunig, D., Rapp, T., Iredale, P., et al. (2013). Systems pharmacology modeling in neuroscience: prediction and outcome of PF-04995274, a 5HT4 partial agonist, in a clinical scopolamine impairment trial. Adv. Alzheimers Dis. 2, 83-98. doi: 10.4236/aad.2013.23012
41. Norén, U., Björner, A., Sonesson, O., and Eriksson, L. (2006). Galantamine added to antipsychotic treatment in chronic schizophrenia: cognitive improvement? Schizophr. Res. 85, 302-304. doi: 10.1016/j.schres.2006.03.039
42. Ogino, S., Miyamoto, S., Miyake, N., and Yamaguchi, N. (2014). Benefits and limits of anticholinergic use in schizophrenia: focusing on its effect on cognitive function. Psychiatry Clin. Neurosci. 68, 37-49. doi: 10.1111/pcn.12088
43. Puig, M. V. (2004). In Vivo excitation of GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors. Cereb. Cortex 14, 1365-1375. doi: 10.1093/cercor/bhh097
44. Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., and Möbius, H. J. (2003). Memantine in moderate-to-severe Alzheimer's disease. N. Engl. J. Med. 348, 1333-1341. doi: 10.1056/nejmoa013128
45. Ribeiz, S. R., Bassitt, D. P., Arrais, J. A., Avila, R., Steffens, D. C., and Bottino, C. M. (2010). Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. CNS Drugs 24, 303-317. doi: 10.2165/11530260-000000000-00000
46. Roberts, P. D., Spiros, A., and Geerts, H. (2012). Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action. Alzheimers Res. Ther. 4, 50. doi: 10.1186/alzrt153
47. Sacco, K. A., Creeden, C., Reutenauer, E. L., and George, T. P. (2008). Effects of galantamine on cognitive deficits in smokers and non-smokers with schizophrenia. Schizophr. Res. 103, 326-327. doi: 10.1016/j.schres.2008.05.004
48. Samochocki, M., Hoffle, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., et al. (2003). Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 305, 1024-1036. doi: 10.1124/jpet.102.045773
49. Samochocki, M., Zerlin, M., Jostock, R., Groot Kormelink, P. J., Luyten, W. H., Albuquerque, E. X., et al. (2000). Galantamine is an allosterically potentiating ligand of the human alpha4/beta2 nAChR. Acta Neurol. Scand. Suppl. 176, 68-73. doi: 10.1034/j.1600-0404.2000.00310.x
50. Saykin, A. J., Shtasel, D. L., Gur, R. E., Kester, D. B., Mozley, L. H., Stafiniak, P., et al. (1994). Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch. Gen. Psychiatry 51, 124-131. doi: 10.1001/archpsyc.1994.03950020048005
51. Schubert, M. H., Young, K. A., and Hicks, P. B. (2006). Galantamine improves cognition in schizophrenic patients stabilized on risperidone. Biol. Psychiatry 60, 530-533. doi: 10.1016/j.biopsych.2006.04.006
52. Shinotoh, H., Aotsuka, A., Fukushi, K., Nagatsuka, S., Tanaka, N., Ota, T., et al. (2001). Effect of donepezil on brain acetylcholinesterase activity in patients with AD measured by PET. Neurology 56, 408-410. doi: 10.1212/WNL.56.3.408
53. Spiros, A., Carr, R., and Geerts, H. (2010). Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr. Dis. Treat. 6, 589-603. doi: 10.2147/NDT.S12460
54. Spiros, A., Roberts, P., and Geerts, H. (2012). A quantitative systems pharmacology computer model for schizophrenia efficacy and extrapyramidal side effects. Drug Dev. Res. 73, 196-213. doi: 10.1002/ddr.21008
55. Spiros, A., and Geerts, H. (2012). A quantitative way to estimate clinical off-target effects for human membrane brain targets in CNS Research and Development. J. Exp. Pharmacol. 4, 53-62. doi: 10.2147/JEP.S30808
56. Takekita, Y., Fabbri, C., Kato, M., Nonen, S., Sakai, S., Sunada, N., et al. (2015). HTR1A gene polymorphisms and 5-HT1A receptor partial agonist antipsychotics efficacy in schizophrenia. J. Clin. Psychopharmacol. 35, 220-227. doi: 10.1097/JCP.0000000000000304
57. Tan, C. C., Yu, J. T., Wang, H. F., Tan, M. S., Meng, X. F., Wang, C., et al. (2014). Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis. J. Alzheimers Dis. 41, 615-631. doi: 10.3233/JAD-132690
58. Tariot, P. N., Solomon, P. R., Morris, J. C., Kershaw, P., Lilienfeld, S., and Ding, C. (2000). A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 54, 2269-2276. doi: 10.1212/wnl.54.12.2269
59. Uchida, H., Rajji, T. K., Mulsant, B. H., Kapur, S., Pollock, B. G., Graff-Guerrero, A., et al. (2009). D2 receptor blockade by risperidone correlates with attention deficits in late-life schizophrenia. J. Clin. Psychopharmacol. 29, 571-575. doi: 10.1097/JCP.0b013e3181bf4ea3
60. Volk, D. W., and Lewis, D. A. (2002). Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. Physiol. Behav. 77, 501-505. doi: 10.1016/S0031-9384(02)00936-8
61. Williams, G. V., and Goldman-Rakic, P. S. (1995). Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572-575. doi: 10.1038/376572a0
62. Winterer, G., Ziller, M., Dorn, H., Frick, K., Mulert, C., Wuebben, Y., et al. (2000). Schizophrenia: reduced signal-to-noise ratio and impaired phase-locking during information processing. Clin. Neurophysiol. 111, 837-849. doi: 10.1016/S1388-2457(99)00322-3
63. Woodruff-Pak, D. S., Lander, C., and Geerts, H. (2002). Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 8, 405-426. doi: 10.1111/j.1527-3458.2002.tb00237.x
64. Zappettini, S., Grilli, M., Lagomarsino, F., Cavallero, A., Fedele, E., and Marchi, M. (2011). Presynaptic nicotinic alpha7 and non-alpha7 receptors stimulate endogenous GABA release from rat hippocampal synaptosomes through two mechanisms of action. PLoS ONE 6:e16911. doi: 10.1371/journal.pone.0016911
65. Zhu, W., Zhang, Z., Qi, J., Liu, F., Chen, J., Zhao, J., et al. (2014). Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study. Neuropsychiatr. Dis. Treat. 10, 1317-1323. doi: 10.2147/NDT.S64189